(Q43777085)

26 November 2017

0 references

Emerging perspectives on lipid management: international approaches and global challenges (English)

1 reference

26 November 2017

Gotto AM Jr

1

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 October 2001

1 reference

American Journal of Cardiology

26 November 2017

published in

1 reference

26 November 2017

volume

88

1 reference

26 November 2017

issue

8

1 reference

26 November 2017

page(s)

876-881

1 reference

Maximizing the cost-effectiveness of lipid-lowering therapy

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901895-1

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901895-1

Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901895-1

Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901895-1

Molecular bases of the acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901895-1

Low-density lipoprotein-independent effects of statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901895-1

Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901895-1

Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901895-1

C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901895-1

Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901895-1

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901895-1

Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901895-1

Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901895-1

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901895-1

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901895-1

Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901895-1

HMG-CoA reductase inhibitors and the risk of fractures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901895-1

Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901895-1

Statins and the risk of dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901895-1

Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901895-1

The National Cholesterol Education Program: progress and prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901895-1

Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901895-1

Prediction of Coronary Heart Disease Using Risk Factor Categories

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901895-1

Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901895-1

Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901895-1

The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901895-1

10.1016/S0002-9149(01)01895-1

7 January 2021

Identifiers

DOI

1 reference

26 November 2017

1 reference